An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis

N. Kawanaka, M. Yamamura, H. Hashimoto, H. Okamoto, Y. Morita, M. Kawashima, T. Aita, A. Okamoto, Hirofumi Makino

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The efficacy and safety of minocycline was investigated in Japanese patients with rheumatoid arthritis (RA) who had already received more than three disease modifying anti-rheumatic drugs (DMARDs). Minocycline was administered at 100 mg twice a day to fifteen patients with active RA. The drug efficacy was evaluated by the clinical variables including the number of painful and/or swollen joints, the duration of morning stiffness, grip strength, the erythrocyte sedimentation rate, serum concentrations of C- reactive protein, and the titer of rheumatoid factor. Three patients experienced adverse effects such as dizziness and abdominal pain or discomfort, but only one patient with abdominal pain and dizziness was discontinued. Fourteen RA patients, who had taken minocycline for at least 6 months, were subjected to the clinical evaluation. Among them, 8 patients (54%) showed a significant improvement of clinical valuables for disease activity, beginning even at 4 weeks of the therapy. The continued effects were observed in 8 patients with over 1 year-minocycline therapy. Intriguingly, an active patient with a history of multiple DMARDs-resistancy showed a marked favorable response to this drug. The present study indicates that minocycline may be an effective DMARD with highly safe performance for patients with active and refractory RA. This is the first demonstration of the benefit of minocycline in the Japanese patients.

Original languageEnglish
Pages (from-to)801-809
Number of pages9
JournalRyumachi
Volume38
Issue number6
Publication statusPublished - Dec 1 1998

Fingerprint

Minocycline
Antirheumatic Agents
Rheumatoid Arthritis
Dizziness
Abdominal Pain
Rheumatoid Factor
Blood Sedimentation
Hand Strength
Pharmaceutical Preparations
C-Reactive Protein
Joints
Safety

Keywords

  • Disease modifying anti-rheumatic drug (DMARD)
  • Lansbury articular index
  • Minocycline
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Kawanaka, N., Yamamura, M., Hashimoto, H., Okamoto, H., Morita, Y., Kawashima, M., ... Makino, H. (1998). An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis. Ryumachi, 38(6), 801-809.

An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis. / Kawanaka, N.; Yamamura, M.; Hashimoto, H.; Okamoto, H.; Morita, Y.; Kawashima, M.; Aita, T.; Okamoto, A.; Makino, Hirofumi.

In: Ryumachi, Vol. 38, No. 6, 01.12.1998, p. 801-809.

Research output: Contribution to journalArticle

Kawanaka, N, Yamamura, M, Hashimoto, H, Okamoto, H, Morita, Y, Kawashima, M, Aita, T, Okamoto, A & Makino, H 1998, 'An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis', Ryumachi, vol. 38, no. 6, pp. 801-809.
Kawanaka N, Yamamura M, Hashimoto H, Okamoto H, Morita Y, Kawashima M et al. An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis. Ryumachi. 1998 Dec 1;38(6):801-809.
Kawanaka, N. ; Yamamura, M. ; Hashimoto, H. ; Okamoto, H. ; Morita, Y. ; Kawashima, M. ; Aita, T. ; Okamoto, A. ; Makino, Hirofumi. / An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis. In: Ryumachi. 1998 ; Vol. 38, No. 6. pp. 801-809.
@article{86c37b1941a1447db9f6b722af95c1f4,
title = "An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis",
abstract = "The efficacy and safety of minocycline was investigated in Japanese patients with rheumatoid arthritis (RA) who had already received more than three disease modifying anti-rheumatic drugs (DMARDs). Minocycline was administered at 100 mg twice a day to fifteen patients with active RA. The drug efficacy was evaluated by the clinical variables including the number of painful and/or swollen joints, the duration of morning stiffness, grip strength, the erythrocyte sedimentation rate, serum concentrations of C- reactive protein, and the titer of rheumatoid factor. Three patients experienced adverse effects such as dizziness and abdominal pain or discomfort, but only one patient with abdominal pain and dizziness was discontinued. Fourteen RA patients, who had taken minocycline for at least 6 months, were subjected to the clinical evaluation. Among them, 8 patients (54{\%}) showed a significant improvement of clinical valuables for disease activity, beginning even at 4 weeks of the therapy. The continued effects were observed in 8 patients with over 1 year-minocycline therapy. Intriguingly, an active patient with a history of multiple DMARDs-resistancy showed a marked favorable response to this drug. The present study indicates that minocycline may be an effective DMARD with highly safe performance for patients with active and refractory RA. This is the first demonstration of the benefit of minocycline in the Japanese patients.",
keywords = "Disease modifying anti-rheumatic drug (DMARD), Lansbury articular index, Minocycline, Rheumatoid arthritis",
author = "N. Kawanaka and M. Yamamura and H. Hashimoto and H. Okamoto and Y. Morita and M. Kawashima and T. Aita and A. Okamoto and Hirofumi Makino",
year = "1998",
month = "12",
day = "1",
language = "English",
volume = "38",
pages = "801--809",
journal = "Ryumachi",
issn = "0300-9157",
publisher = "Nihon Ryumachi Gakkai",
number = "6",

}

TY - JOUR

T1 - An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis

AU - Kawanaka, N.

AU - Yamamura, M.

AU - Hashimoto, H.

AU - Okamoto, H.

AU - Morita, Y.

AU - Kawashima, M.

AU - Aita, T.

AU - Okamoto, A.

AU - Makino, Hirofumi

PY - 1998/12/1

Y1 - 1998/12/1

N2 - The efficacy and safety of minocycline was investigated in Japanese patients with rheumatoid arthritis (RA) who had already received more than three disease modifying anti-rheumatic drugs (DMARDs). Minocycline was administered at 100 mg twice a day to fifteen patients with active RA. The drug efficacy was evaluated by the clinical variables including the number of painful and/or swollen joints, the duration of morning stiffness, grip strength, the erythrocyte sedimentation rate, serum concentrations of C- reactive protein, and the titer of rheumatoid factor. Three patients experienced adverse effects such as dizziness and abdominal pain or discomfort, but only one patient with abdominal pain and dizziness was discontinued. Fourteen RA patients, who had taken minocycline for at least 6 months, were subjected to the clinical evaluation. Among them, 8 patients (54%) showed a significant improvement of clinical valuables for disease activity, beginning even at 4 weeks of the therapy. The continued effects were observed in 8 patients with over 1 year-minocycline therapy. Intriguingly, an active patient with a history of multiple DMARDs-resistancy showed a marked favorable response to this drug. The present study indicates that minocycline may be an effective DMARD with highly safe performance for patients with active and refractory RA. This is the first demonstration of the benefit of minocycline in the Japanese patients.

AB - The efficacy and safety of minocycline was investigated in Japanese patients with rheumatoid arthritis (RA) who had already received more than three disease modifying anti-rheumatic drugs (DMARDs). Minocycline was administered at 100 mg twice a day to fifteen patients with active RA. The drug efficacy was evaluated by the clinical variables including the number of painful and/or swollen joints, the duration of morning stiffness, grip strength, the erythrocyte sedimentation rate, serum concentrations of C- reactive protein, and the titer of rheumatoid factor. Three patients experienced adverse effects such as dizziness and abdominal pain or discomfort, but only one patient with abdominal pain and dizziness was discontinued. Fourteen RA patients, who had taken minocycline for at least 6 months, were subjected to the clinical evaluation. Among them, 8 patients (54%) showed a significant improvement of clinical valuables for disease activity, beginning even at 4 weeks of the therapy. The continued effects were observed in 8 patients with over 1 year-minocycline therapy. Intriguingly, an active patient with a history of multiple DMARDs-resistancy showed a marked favorable response to this drug. The present study indicates that minocycline may be an effective DMARD with highly safe performance for patients with active and refractory RA. This is the first demonstration of the benefit of minocycline in the Japanese patients.

KW - Disease modifying anti-rheumatic drug (DMARD)

KW - Lansbury articular index

KW - Minocycline

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0032449150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032449150&partnerID=8YFLogxK

M3 - Article

C2 - 10047718

AN - SCOPUS:0032449150

VL - 38

SP - 801

EP - 809

JO - Ryumachi

JF - Ryumachi

SN - 0300-9157

IS - 6

ER -